Physician profile
Stuart Marshall Klein
NPI 1790870483
$939.06
in general payments reported to CMS, 2019-2025
15 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $49.48 · 2021: $209 · 2022: $125 · 2023: $79.10 · 2024: $60.55 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.22 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $202.47 | 2021-2024 | Repatha, Otezla |
| Novo Nordisk INC | $136.98 | 2019-2025 | |
| Intuitive Surgical, INC. | $127.27 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.75 | 2019-2021 | |
| Lilly USA, LLC | $98.70 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $52.07 | 2019-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $38.00 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.20 | 2022 | |
| Mylan Specialty L.P. | $30.85 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $23.28 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $20.62 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.49 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.45 | 2024 | Quviviq |
| Glaxosmithkline, LLC. | $13.68 | 2019 | |
| Dexcom, INC. | $13.25 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.